Year All 2026 2025 September 29, 2026 Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis September 8, 2026 Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis September 4, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 1, 2026 Vor Bio To Participate in Upcoming September Conferences August 11, 2026 Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 3, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 7, 2026 Vor Bio Appoints David Zaccardelli to Board of Directors July 2, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 8, 2026 Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China June 8, 2026 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
September 29, 2026 Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 8, 2026 Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
June 8, 2026 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China